Dec 26, 2023 00:45
5 mos ago
32 viewers *
English term
Russian Federation
Medical/Technical/Marketing Translations
Native in: Russian
Works in: English to Russian
10 mg step dose
English to Russian
Medical
Medical: Pharmaceuticals
investigator brochure
1 mg run-in dose on cycle 1 day 1 and stepped up to 10 mg target dose on cycle 1 days 8 and 15, and every 2 weeks thereafter at target dose
In the 10 and 100 mg step dose groups...
In the 10 and 100 mg step dose groups...
Proposed translations
(Russian)
| 3 +1 | целевая доза, достигаемая пошаговым увеличением, 10 мг |
Edgar Hermann
|
Proposed translations
+1
9 hrs
Edgar Hermann
Native in Russian
4 years with GAZPROM, university degree
Native in: Russian (Variant: Standard-Russia) 
Works in: English to Russian, German to Russian
Related KudoZ points
:
88
Selected
целевая доза, достигаемая пошаговым увеличением, 10 мг
группы с пошаговым увеличением дозы до целевого значения 10 и 100 мг
4 KudoZ points awarded for this answer.
Reference comments
11 hrs
Reference:
https://rosoncoweb.ru/news/oncology/2023/12/06/
--------------------------------------------------
Note added at 11 hrs (2023-12-26 12:11:38 GMT)
--------------------------------------------------
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980545/
Using the body’s immune system to recognize and kill cancer cells is an enticing prospect within oncology, showing great promise with several different therapeutic approaches. Among these are bispecific T-cell engagers (TCE), which can overcome some of the limitations of the body’s natural immune system by recruiting T cells to the tumor site and stimulating their activation and proliferation to help override the immune escape mechanisms developed by cancer cells.
Emerging data from clinical trials of TCEs continue to provide insights on the efficacy and safety profiles of this class of therapy, and recent efforts have focused on optimizing clinical dose regimens to mitigate side effects related to overstimulation of the immune system, with particular emphasis on cytokine release syndrome (CRS) and neurotoxicity.
For the currently approved TCEs, a key discovery was that by incrementally increasing the dose administered to a patient before reaching the target dose level, the body’s immune system could be primed in a more gradual manner, thereby modulating the balance between T cell activation and expansion, and cytokine-mediated efficacy and toxicity. This is known as step-up dosing, and various forms of this approach have been used to optimize TCE dose regimens to reduce the incidence or severity of CRS during clinical trials.
--------------------------------------------------
Note added at 11 hrs (2023-12-26 12:11:38 GMT)
--------------------------------------------------
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980545/
Using the body’s immune system to recognize and kill cancer cells is an enticing prospect within oncology, showing great promise with several different therapeutic approaches. Among these are bispecific T-cell engagers (TCE), which can overcome some of the limitations of the body’s natural immune system by recruiting T cells to the tumor site and stimulating their activation and proliferation to help override the immune escape mechanisms developed by cancer cells.
Emerging data from clinical trials of TCEs continue to provide insights on the efficacy and safety profiles of this class of therapy, and recent efforts have focused on optimizing clinical dose regimens to mitigate side effects related to overstimulation of the immune system, with particular emphasis on cytokine release syndrome (CRS) and neurotoxicity.
For the currently approved TCEs, a key discovery was that by incrementally increasing the dose administered to a patient before reaching the target dose level, the body’s immune system could be primed in a more gradual manner, thereby modulating the balance between T cell activation and expansion, and cytokine-mediated efficacy and toxicity. This is known as step-up dosing, and various forms of this approach have been used to optimize TCE dose regimens to reduce the incidence or severity of CRS during clinical trials.
Discussion